RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 4

Registered title, quoted from ClinicalTrials.gov

Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Shanghai Pulmonary Hospital; 2 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 3

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorShanghai Pulmonary Hospital上海市肺科医院ShanghaiHospital page
  2. Study siteGuangdong Provincial People's Hospital广东省人民医院GuangzhouHospital page
  3. Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07754812, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 70 years to Not stated; sex: all

    Registered eligibility fields

  2. Histologically confirmed non-small cell lung cancer, clinical stage IIA-IIIB according to the 8th edition of the AJCC staging system.

    Inclusion criterion 3

  3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

    Inclusion criterion 2

  4. No sensitizing driver alterations in EGFR, ALK, ROS1, or other tested actionable genes.

    Inclusion criterion 6

    Absolute neutrophil count at least 1.5 × 10\^9/L, platelet count at least 100 × 10\^9/L, and hemoglobin at least 9 g/dL.

    Inclusion criterion 8

    Total bilirubin no more than 1.5 × the upper limit of normal; alanine aminotransferase and aspartate aminotransferase no more than 2.5 × the upper limit of normal.

    Inclusion criterion 9

    Serum creatinine no more than 1.5 × the upper limit of normal or creatinine clearance at least 60 mL/min.

    Inclusion criterion 10

  5. Another concurrent malignancy or a history of another malignancy cured less than 5 years before enrollment, except adequately treated cervical carcinoma in situ or basal cell or squamous cell carcinoma of the skin.

    Exclusion criterion 2

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; scans and measurable lesions; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07754812, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age 70 years or older, regardless of sex.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Histologically confirmed non-small cell lung cancer, clinical stage IIA-IIIB according to the 8th edition of the AJCC staging system.
  • No evidence of distant metastasis and considered suitable for radical lung cancer surgery.
  • The primary lung lesion is suitable for stereotactic body radiotherapy.
  • No sensitizing driver alterations in EGFR, ALK, ROS1, or other tested actionable genes.
  • Adequate major organ function, including all of the following:
  • Absolute neutrophil count at least 1.5 × 10\^9/L, platelet count at least 100 × 10\^9/L, and hemoglobin at least 9 g/dL.
  • Total bilirubin no more than 1.5 × the upper limit of normal; alanine aminotransferase and aspartate aminotransferase no more than 2.5 × the upper limit of normal.
  • Serum creatinine no more than 1.5 × the upper limit of normal or creatinine clearance at least 60 mL/min.
  • Urine protein less than 1+; if urine protein is 1+, 24-hour urine protein must be less than 500 mg.
  • Blood glucose within the normal range or stable glycemic control in participants with diabetes.
  • Baseline forced expiratory volume in 1 second (FEV1) at least 2 L; if FEV1 is less than 2 L, the predicted postoperative FEV1 must be greater than 800 mL as assessed by a thoracic surgeon.
  • No myocardial infarction within the previous year, no unstable angina, no symptomatic severe arrhythmia, and no cardiac insufficiency.
  • The participant has been fully informed and voluntarily provides written informed consent.

Exclusion Criteria:

  • Prior lobectomy, thoracic radiotherapy, or systemic antitumor therapy.
  • Another concurrent malignancy or a history of another malignancy cured less than 5 years before enrollment, except adequately treated cervical carcinoma in situ or basal cell or squamous cell carcinoma of the skin.
  • Active autoimmune disease or a history of autoimmune disease requiring systemic immunosuppressive treatment.
  • Active infection requiring systemic treatment, active tuberculosis, human immunodeficiency virus infection, active hepatitis B or hepatitis C, active syphilis, or another active transmissible infection specified by the protocol.
  • Severe cardiac, hepatic, renal, or metabolic disease that precludes surgery or study treatment.
  • History of interstitial lung disease or drug-induced pneumonitis, or imaging evidence of active interstitial lung disease.
  • Uncontrolled large pleural effusion or pericardial effusion.
  • Major surgery, severe trauma, or treatment with another investigational drug within 4 weeks before enrollment.
  • Recent receipt of an anticancer vaccine or live vaccine.
  • Any other condition that, in the investigator's opinion, makes the participant unsuitable for the study or may interfere with interpretation of the study results.

Quoted from ClinicalTrials.gov, NCT07754812, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07754812, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07754812